Senti Biosciences Holdings (SNTI) Cash from Operations (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Cash from Operations of 6875000.0 for Q4 2025, up 49.09% year-over-year from 4611334.62 in Q4 2024, and up 27.22% quarter-over-quarter from 9446000.0 in Q3 2025.
Senti Biosciences Holdings (SNTI) Cash from Operations (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Cash from Operations history runs 5 years deep, the most recent figure standing at 6875000.0 for Q4 2025.
- In Q4 2025, Cash from Operations rose 49.09% year-over-year to 6875000.0; the TTM figure through Dec 2025 stood at 43444000.0 (down 4.94% YoY), while the FY2025 annual figure was 43444000.0, down 4.94% from the prior year.
- Cash from Operations for Q4 2025 stood at 6875000.0, up from 9446000.0 in the prior quarter.
- The five-year high for Cash from Operations was 934675.0 in Q2 2021, with the low at 16304000.0 in Q1 2023.
- The 5-year median for Cash from Operations is 9446000.0 (2025), against an average of 9223997.26.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 868.08% in 2022, then surged 49.09% in 2025.
- Senti Biosciences Holdings' Cash from Operations stood at 1142247.0 in 2021, then plunged by 688.45% to 9006000.0 in 2022, then advanced by 21.86% to 7037000.0 in 2023, then slumped by 91.9% to 13504000.0 in 2024, then soared by 49.09% to 6875000.0 in 2025.
- Business Quant data shows SNTI's Cash from Operations at 6875000.0 in Q4 2025, 9446000.0 in Q3 2025, and 13073000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.88 Mn |
| Dec 31, 2025 | -6.88 Mn |
| Sep 30, 2025 | -9.45 Mn |
| Sep 30, 2025 | -9.45 Mn |
| Jun 30, 2025 | -13.07 Mn |
| Jun 30, 2025 | -13.07 Mn |
| Mar 31, 2025 | -14.05 Mn |
| Mar 31, 2025 | -14.05 Mn |
| Dec 31, 2024 | -13.50 Mn |
| Dec 31, 2024 | -13.50 Mn |
| Sep 30, 2024 | -7.87 Mn |
| Sep 30, 2024 | -7.87 Mn |
| Jun 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | -8.35 Mn |
| Mar 31, 2024 | -11.68 Mn |
| Mar 31, 2024 | -11.68 Mn |
| Dec 31, 2023 | -7.04 Mn |
| Dec 31, 2023 | -7.04 Mn |
| Sep 30, 2023 | -15.38 Mn |
| Sep 30, 2023 | -15.38 Mn |